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Background: Treatments for childhood obesity are critically needed because of the risk of developing co-morbidities,
although the interventions are frequently time-consuming, frustrating, difficult, and expensive.
Patients and methods: We conducted a longitudinal, randomised, clinical study, based on a per protocol analysis,
on 133 obese children and adolescents (n = 69 males and 64 females; median age, 11.3 years) with family history of
obesity and type 2 diabetes mellitus (T2DM). The patients were divided into three arms: Arm A (n = 53 patients), Arm B
(n = 45 patients), and Arm C (n = 35 patients) patients were treated with a low-glycaemic-index (LGI) diet and Policaptil
Gel Retard®, only a LGI diet, or only an energy-restricted diet (ERD), respectively. The homeostasis model assessment
of insulin resistance (HOMA-IR) and the Matsuda, insulinogenic and disposition indexes were calculated at T0 and after
1 year (T1).
Results: At T1, the BMI-SD scores were significantly reduced from 2.32 to 1.80 (p < 0.0001) in Arm A and from 2.23
to 1.99 (p < 0.05) in Arm B. Acanthosis nigricans was significantly reduced in Arm A (13.2% to 5.6%; p < 0.05), and
glycosylated-haemoglobin levels were significantly reduced in Arms A (p < 0.005). The percentage of glucose-
metabolism abnormalities was reduced, although not significantly. However, the HOMA-IR index was significantly
reduced in Arms A (p < 0.0001) and B (p < 0.05), with Arm A showing a significant reduction in the insulinogenic index
(p < 0.05). Finally, the disposition index was significantly improved in Arms A (p < 0.0001) and B (p < 0.05).
Conclusions: A LGI diet, particularly associated with the use of Policaptil Gel Retard®, may reduce weight gain and
ameliorate the metabolic syndrome and insulin-resistance parameters in obese children and adolescents with family
history of obesity and T2DM.
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Childhood obesity, which is recognised as a major public
health issue, has been increasing worldwide during the
last several decades [1]. More than one-third of children
and adolescents are reportedly at risk of being over-
weight or obese in Italy [2] and in many countries of
Europe [3-5]. The need for evidence-based treatment
recommendations is a critical healthcare issue because
obese children and adolescents are at risk for developing
many co-morbidities observed in obese adults. This
increase in weight, as well as the decrease in physical ac-
tivity and cardiorespiratory fitness levels [6], are in direct
proportion to an increasing prevalence of impaired glu-
cose tolerance (IGT) [7], metabolic syndrome (MetS)
[8,9], and type 2 diabetes (T2DM) [10]. Nevertheless,
many data show lower rates in Europe compared to
North American data [11].
The treatment of childhood obesity is frequently time-
consuming, frustrating, difficult, and expensive [12]. Many
interventions have focused on changing individual behav-
iour to prevent excessive childhood weight gain; however,
this strategy has generally led only to short-term improve-
ments, if any, in obesity and its related risk factors [13].
Obesity is challenging to treat because of multiple physio-
logical, behavioural, and cultural feedback loops [14].
According to the energy balance model, a change in
body weight is equal to the energy intake minus the en-
ergy expenditure. However, many studies have shown
that energy input and expenditure are interdependent
and are regulated at several levels, which suggests that a
more intricate model operates to regulate energy balance
and to maintain body weight [15].
Dietary recommendations are a central component of
any comprehensive weight-loss programme and various
alternative dietary interventions, such as energy restric-
ted diets (ERD), reduced carbohydrate diets, and low-
glycaemic-index (LGI) diets, have been proposed [16].
An ERD is the conventional treatment for obesity; how-
ever, the results indicate that it is not easy to follow and
that it is difficult to achieve and maintain weight loss.
Satiety is inversely related to the glycaemic and insulinae-
mic responses, and diets that reduce the insulin response
may better promote long-term weight loss by decreasing
hunger [15].
The purpose of this study was to compare the effects
of a LGI diet in conjunction with Policaptil Gel Retard®,
a new complex of polysaccharide macromolecules slow-
ing the rate of carbohydrate and fat absorption, and LGI
and ERD diets alone on the glucose metabolism parame-
ters in three cohorts of obese children and adolescents.
Subjects and methods
This longitudinal, randomised, clinical study, based on a
per protocol analysis, enrolled 150 obese patients (n = 75males, 75 females; median age at the onset of the study,
11.4 years; age range, 8.0–13.8 years) with familial
forms of obesity and T2DM, consecutively evaluated
between February 2012 and February 2014 at Anna
Meyer Children’s University Hospital in Florence, and at
Mugello’s Hospital in Borgo San Lorenzo, Florence, Italy.
The study was approved by the competent Ethics Com-
mittees and was conducted according to the Declaration
of Helsinki. Informed written consent was obtained from
the subjects’ parents before their participation in the
study.
Study design
The children and adolescents were recruited before thera-
peutic intervention began (T0) and were monitored for
1 year (T1) (median, 11.9 months; range, 8.1–13.3 months).
These subjects were randomly divided into three groups
that were matched according to age, sex, and body mass
index (BMI) (Figure 1).
The exclusion criteria were as follows: patients youn-
ger than 8 years and older than 16 years, a pre-existing
T2DM, Cushing syndrome, untreated hypothyroidism,
severe asthma, use of medications known to promote
weight gain or loss, obesity-associated genetic syndromes,
chronic diseases, or systemic inflammation [17].
Randomisation was performed using a computer-
generated random number table with 1.3:1:1 randomisa-
tion (Arm A, 60 subjects; Arm B, 45 subjects; Arm C, 45
subjects). Auxological data and laboratory measurements
were obtained at baseline and at 3–6 months and
12 months.
Of the 150 patients initially recruited to participate in
this study, 9 (6.0%; n = 2 males, 7 females) declined to par-
ticipate (Figure 1). However, 8 (n = 4 males, 4 females)
dropped out for various reasons (non-compliance, lost to
follow up, etc.), and were excluded from the study: 5
subjects belonged to Arm A (3 dropped out for non-
compliance, 2 for loss to follow up) and 3 subjects
belonged to Arm C (2 dropped out for non-compliance, 1
for loss to follow up); all of the subjects in Arm B
remained in the study. The final count, 133 subjects
(87.2%; 69 males, 64 females; median age at the onset of
the study, 11.3 years; age range, 8.0–13.5 years) completed
the study (Figure 1). However, to avoid the possibility of
misleading artifacts that can arise in a per protocol ana-
lysis, such as non-compliance or drop-outs, we evaluated
the results at T0 and T1 also by an intention-to-treat
(ITT) analysis (141 subjects 73 males, 68 females; median
age at the onset of the study, 11.4 years; age range,
8.0–13.6 years) (Table 1).
Arm A comprised 53 subjects (n = 27 males, 26 fe-
males; median age, 11.7 years; age range, 8.0–13.6 years)
who were treated with a LGI diet and Policaptil Gel
Retard® (Aboca Spa Company, Sansepolcro, Arezzo, Italy).
Figure 1 Summary of patient flow diagram. Individuals with obesity and family history for obesity and T2DM. The patients in Arm A were
treated with a LGI diet and Policaptil Gel Retard® during the study; the patients in Arm B were treated with a LGI diet alone, whereas the patients
in Arm C were treated only with an ERD of reduced carbohydrates and fats.
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median age, 12.0 years; age range, 8.2–13.5 years) who
were treated only with a LGI diet. Arm C comprised 35subjects (n = 19 males, 16 females; median age, 11.8 years;
age range, 8.1–13.1 years) who were treated only with an
ERD of reduced carbohydrates and fats.
Table 1 Primary baseline anthropometric, clinical, and biochemical features of the study groups
Arm A* Arm A° Arm B*° Arm C* Arm C°
Age, years (range) 11.7 (8.0–13.5) 11.7 (8.0–13.6) 12.0 (8.2–13.5) 11.8 (8.1–13.1) 11.8 (8.0–13.2)
N° and sex (male/female) 53 (27/26) 58 (29/29) 45 (23/22) 35 (19/16) 38 (21/17)
Tanner stage
Prepubertal, n (%) 30 (56.6) 33 (56.9) 24 (53.3) 19 (54.3) 21 (55.3)
Pubertal, n (%) 23 (43.4) 25 (43.1) 21 (46.6) 16 (45.7) 17 (44.7)
Prepubertal/pubertal ratio, n (%) 30/23 (56.6/43.4) 33/25 (56.9/43.1) 24/21 (53.3/46.6) 19/16 (54.3/45.7) 21/17 (55.3/44.7)
BMI, SDS 2.32 ± 0.53 2.33 ± 0.57 2.23 ± 0.57 2.27 ± 0.74 2.29 ± 0.77
Acanthosis nigricans, n (%) 7 (13.2) 8 (13.8)1 6 (13.3) 4 (11.4) 5 (13.1)2
Prepubertal, n (%) 2 (3.8) 3 (5.2) 2 (4.4) 1 (2.8) 2 (5.3)
Pubertal, n (%) 5 (9.4) 5 (8.6) 4 (8.9) 3 (8.6) 3 (7.9)
Waist circumference, SDS 4.0 ± 1.4 3.9 ± 1.5 3.8 ± 1.1 4.1 ± 1.3 4.0 ± 1.3
Hip circumference, SDS 3.2 ± 1.0 3.3 ± 1.1 3.1 ± 1.3 3.2 ± 1.2 3.3 ± 1.2
Systolic BP, mmHg 115.9 ± 8.7 116.5 ± 8.8 118.2 ± 8.7 120.1 ± 7.9 119.8 ± 8.0
Diastolic BP, mmHg 68.2 ± 8.9 69.5.2 ± 8.9 69.4 ± 9.3 69.4 ± 8.6 69.9 ± 8.7
Fasting glucose, mg/dL 90.62 ± 4.32 91.23 ± 4.39 89.63 ± 3.17 90.90 ± 5.71 90.12 ± 5.79
Fasting insulin, μU/mL 27.60 ± 7.83 27.48 ± 7.92 26.71 ± 9.36 27.39 ± 8.61 27.46 ± 8.55
HbA1c, %, mmol/mol 5.63 ± 0.54 5.66 ± 0.57 5.70 ± 0.52 5.68 ± 0.58 5.69 ± 0.59
HOMA-IR, mean (range) 5.69 (3.60–9.92) 5.76 (3.60–10.67) 5.68 (2.00–10.90) 5.78 (4.21–8.89) 5.76 (3.21–8.89)
Prepubertal 5.61 (3.60–8.04) 5.72 (3.60–10.67) 4.72 (2.00–8.38) 5.32 (3.25–7.98) 5.32 (3.21–7.98)
Pubertal 7.41 (4.67–9.92) 7.39 (4.67–9.92) 6.31 (3.82–10.90) 7.19 (4.38–8.89) 7.19 (4.38–8.89)
ISOGTT, SDS 1.40 ± 0.24 1.42 ± 0.26 1.42 ± 0.22 1.56 ± 0.48 1.58 ± 0.49
Prepubertal 1.51 ± 0.15 1.52 ± 0.16 1.79 ± 0.55 1.56 ± 0.11 1.59 ± 0.15
Pubertal 1.27 ± 0.27 1.29 ± 0.31 1.35 ± 0.55 1.30 ± 0.22 1.31 ± 0.23
Insulinogenic index, mean (range) 3.66 (1.90–9.25) 3.61 (1.70–9.25) 2.54 (1.91–10.2) 3.12 (1.15–9.70) 3.07 (1.13–9.70)
Prepubertal 3.43 (2.29–9.25) 3.42 (2.29–9.25) 2.57 (1.29–10.26) 3.94 (2.51–9.70) 3.94 (2.51–9.70)
Pubertal 2.98 (1.90–6.36) 2.95 (1.70–6.36) 1.75 (0.63–4.30) 2.25 (1.15–3.24) 2.25 (1.13–3.29)
Disposition index, mean (range) 4.42 (2.25–11.97) 4.48 (2.22–12.02) 4.01 (0.83–11.72) 3.79 (1.88–9.28) 3.84 (1.88–14.78)
Prepubertal 5.52 (2.25–11.97) 5.55 (2.22–12.02) 4.59 (2.31–11.72) 5.68 (4.30–14.78) 5.69 (4.30–14.78)
Pubertal 4.42 (2.99–6.76) 4.44 (2.73–6.76) 2.48 (0.83–5.67) 2.72 (1.99–3.79) 2.79 (1.88–6.39)
Glucose metabolism abnormalities, n (%) 8 (15.1) 9 (15.5) 6 (13.3) 4 (11.4) 5 (11.4)
IGT 6 (11.3) 7 (12.1)1 5 (11.1) 4 (11.4) 4 (10.5)
T2DM 2 (3.8) 2 (3.4) 1 (2.2) - 1 (2.6)2
BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model of assessment for insulin-resistance; ISOGTT, Matsuda index; SDS, standard deviation
score; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus; *per protocol analysis; °intention to treat analysis. 1patient with acanthosis nigricans and
IGT dropped out in the per protocol analysis for non-compliance: 2patient with acanthosis nigricans and T2DM dropped out in the per protocol analysis for
non-compliance.
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The number of subjects required to compare the abil-
ities of the three treatment arms to achieve a reduc-
tion in BMI of at least0.5 SDS and to detect a change
of at least 10 μU/mL in basal insulin levels between
the groups was calculated with a significance level of
5% and a power of 90%. The aim was to include at
least a 1.3:1:1 ratio due to a higher withdrawal rate ex-
pected in Arm A.Study protocol
During the interventional study (T0 and T1), trained ex-
perts collected and assessed the clinical and demo-
graphic data, including height, weight, body mass index
(BMI), pubertal stage, waist and hip circumference, and
the time dedicated to outdoor physical activity. Further-
more, nutrient diaries were recorded for each subject
based on his/her medical charts and standardised inter-
views. Blood samples (fasting and after glucose loading)
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paediatric nurses [17].
Obesity was defined based on the reference values in
growth charts as shown in the study by Cacciari et al.
[18] Children with a BMI greater than the 95th percent-
ile for their age and gender were classified as obese.
Those with BMIs equal to or exceeding the 85th per-
centile but below the 95th percentile were defined as
overweight [19,20].
Policaptil Gel Retard® is the API (Active Pharmaceutical
Ingredient) of the Medical Device in tablets, Libramed
(Aboca Spa Company, Sansepolcro, Arezzo, Italy). This
complex is composed of polysaccharidic macromolecules
(cellulose, hemicellulose, pectin, mucilages) and is derived
from the following raw materials rich in fibres: glucoman-
nan (Amorphophallus konjac), cellulose, Opuntia pulp
stem (Opuntia ficus indica), chicory root (Cichorium inty-
bus), freeze-dried mallow root mucilage (Althaea officina-
lis), freeze-dried flaxseed mucilage (Linum usitatissimum
L), and freeze-dried linden flower mucilage (Tilia platy-
phyllos Scop). This product slows the rate of carbohydrate
absorption, likely decreasing glycaemic and insulinaemic
peak intensity. The exact composition and the production
process by which the API is obtained is covered by a
European patent (n° 1679009).
All patients of Arm A took 3 tablets before their two
main meals. Compliance was evaluated by means of
written instructions provided at the onset of the study
and at clinical controls through a written questionnaire
completed by the parents. Compliance was verified by
e-mails and telephone interviews performed by a study
nurse (to confirm the use of Policaptil Gel Retard®) and
by the bottle count performed at the end of the study
period.
During the baseline and final medical evaluations, the
parents completed a questionnaire that was reviewed by
an interviewer and included items regarding the subject’s
and his/her family’s lifestyle, such as detailed diet in-
formation, family and personal medical histories, and
current medications [21]. During final evaluation a ques-
tionnaire was completed to assess any side effects that
had occurred during the study.
The reported energy intake (REI) was calculated from
3-day diet records, typically two weekdays and one
weekend day [22]. The families were provided with a
sample food record with written and verbal instructions
for their completion and 2-dimensional food models for
estimating portions.
Daily energy requirements (DER) were calculated
using the Schofield equation [23], which considers age,
sex, height, weight, and physical activity. The REI/DER
ratio was used to classify the intake as presumably
under-reported (<0.8), adequately reported (0.8–1.2), or
over-reported (>1.2) [24]. The physical activity levelswere estimated according to the interview items based
on the behavioural risk factor surveillance system [25].
The glycaemic index (GI) of a test food is defined as
the glucose area under the curve (AUC) after consuming
50 g of carbohydrates of a test food relative to the value
after consuming 50 g of carbohydrates of a standard
food (either white bread or glucose) [26]. The GI of
carbohydrate-containing foods was assigned on the basis
of a glucose reference from published GI values [27]. A
weighted GI for each food item was obtained by multi-
plying the GI by the proportion of total carbohydrates
contributed by the food item. The daily GI was calcu-
lated by summing up the weighted GI values for each
food item [27].
The subjects in the LGI diet groups, with or without
the use of Policaptil Gel Retard®, were instructed to limit
their intake of high GI foods (e.g., white bread and con-
centrated sugars) based on a food classification system
by GI value, where ‘red,’ ‘yellow,’ and ‘green’ foods have
high (≥70), medium (56–69), and low (≤55) GIs, respect-
ively [28]. Green foods were unrestricted (e.g., fruit, non-
starchy vegetables, 100% whole grains, and unbreaded
meat, poultry and fish); yellow foods (e.g., pizza, macaroni
and cheese, corn and dried fruits) were consumed less fre-
quently; and red foods (e.g., sugary drinks, refined baked
goods, candy, white bread and white potatoes) were re-
stricted to ≤7 servings/week [28]. There were no specific
restrictions on energy or fat intake for the LGI groups.
The ERD group was treated with the Traffic Light Diet
to decrease energy, carbohydrate, and fat intake [29].
The Traffic Light Diet foods are categorised as ‘green,’
‘yellow,’ and ‘red’ based on their fat and sugar content
per serving. Green foods, such as fruits and vegetables,
are high in nutrient density and low in energy density
(fat = 0–1 g or sugar <10% calories/serving). Yellow
foods are higher in energy density than green foods
(fat = 2–5 g or sugar = 10–25% calories/serving). Red
foods, such as the fat, oil, and sweet groups, are
higher in energy density (fat >5 g or sugar >25% calo-
ries/serving). Modified foods from the fat, oil, and
sweet groups are considered red foods, although their
fat or energy level is low. However, combination foods
(e.g., sandwiches, pizza, hamburger, and lasagne) are
only considered red food if a serving contains at least
one serving of a red food [29]. The ERD group was
instructed to consume a distribution of macronutrients
of 53% carbohydrates, 17% proteins, and 30% fat. The
induced energy restriction was −30% with respect to the
individually measured DER.
The variables for insulin resistance and β-cell function
were evaluated using an oral glucose tolerance test
(OGTT), carried out at baseline (T0) and at 12 months
(T1). After an overnight fast of 12 h, the patients
ingested 1.75 g of glucose per kilogram of body weight
Stagi et al. Italian Journal of Pediatrics  (2015) 41:10 Page 6 of 12(maximal dose, 75 g), and their glucose and insulin levels
were determined at baseline and 30 min, 60 min,
90 min, and 120 min later [17]. The glycaemic status
was defined based on the 2010 American Diabetes Asso-
ciation criteria [30]: impaired fasting glucose, defined as a
fasting plasma glucose (FPG) of 100–125 mg/dL (5.6–
6.9 mmol/L) without hypoglycaemic treatment; impaired
glucose tolerance (IGT), defined as 2-h values in the
OGTT of 140–199 mg/dL (7.8–11.0 mmol/L); diabetes,
defined as an FPG of ≥126 mg/dL (≥7.0 mmol/L) and 2-h
plasma glucose values during an OGTT of ≥200 mg/dL
(≥11.1 mmol/L).
The homeostasis model assessment of insulin resist-
ance (HOMA-IR), Matsuda index of insulin sensitivity
[31-33], and plasma glucose and insulin AUCs were cal-
culated for all patients. A low HOMA-IR index indicated
high insulin sensitivity, whereas a high HOMA-IR index
indicated low insulin sensitivity (insulin resistance). An
HOMA-IR index above 4.4 was considered to be consist-
ent with insulin resistance [17,33]. The Matsuda index
[32] provided a measure of insulin sensitivity and was
calculated using the following equation:
¼ 10; 000ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
FPG FPIð Þ  mean PGmean PIð Þp
where FPG is fasting plasma glucose, FPI is fasting
plasma insulin, PG is plasma glucose, and PI is plasma
insulin. The Matsuda index of insulin sensitivity is con-
sistent with the direct measurements using an insulin
clamp.
The glucose and insulin AUCs during the OGTT were
calculated using the trapezoidal rule [34]. Delta-glucose
(ΔG30–0) and delta-insulin (ΔI30–0) were evaluated as
the changes in glucose and insulin concentrations from
0 min to 30 min. The insulinogenic index, calculated as
(Ins30 - Ins0)/(Glu30 - Glu0), was used to estimate insu-
lin secretion [35]. The β-cell compensatory capacity was
evaluated using the disposition index (DI), defined as the
product of the Matsuda and insulinogenic indexes [35].
For children aged 10 years and older, MetS was diag-
nosed by abdominal obesity and the presence of two or
more clinical features [i.e., elevated triglycerides (TG), low
high-density lipoprotein (HDL) cholesterol, high blood
pressure, and elevated plasma glucose] [36].
Methods
Height was measured to the nearest 0.1 cm in triplicate
using a Harpenden stadiometer. Weight was determined
to the nearest 0.1 kg using a standard physician’s beam
scale with the subject shoeless and dressed in light
underwear. BMI was calculated as body weight divided
by height squared (kg/m2). The height, weight, and BMI
were stratified using Italian growth charts [37].Waist circumference was measured to the nearest
0.1 cm at the end of normal expiration using a non-
elastic tape measure placed midway between the lowest
rib margin and the iliac crest [38,39]. Hip circumference
was measured to the nearest 0.1 cm using a tape measure
positioned horizontally over the widest part of the gluteal
region as the subject stood relaxed with his/her feet placed
as close together as possible [38,39]. The waist/hip ratio
was calculated using these measurements [40].
The height, weight, BMI, waist circumference, and hip
circumference were normalised for chronological age by
conversion to standard deviation scores (SDSs). Blood
pressure was measured three times by trained personnel
by auscultation using a mercury sphygmomanometer on
the right arm after the patient has been sitting quietly
for 5 minutes, with the back supported, feet on the floor,
right arm supported and cubital fossa at heart level [17].
The mean systolic and diastolic values were recorded
and stratified according to the paediatric percentiles of
the National High Blood Pressure Education Program
Working Group on High Blood Pressure in Children
and Adolescents [17].
Serum glycaemia (Dimension RXL system, Dade
Behring, Dallas, TX, USA) and serum insulin (IMMU-
LITE 2000 analyser, Siemens Healthcare Diagnostics,
Marburg, Germany) levels were measured using im-
munoenzymatic assays, and glycosylated haemoglobin
(HbA1c) levels were determined using high performance
liquid chromatography (DIAMAT, Bio-Rad, Richmond,
CA, USA). The normal range for HbA1c was 4.2–6.0%,
and the coefficient of variation (CV) was 4.8 at 5.5%.
The total cholesterol, HDL cholesterol, and triglycer-
ide (TG) measurements were performed according to
routine laboratory methods. Low-density lipoprotein
(LDL) cholesterol was calculated using the Friedwald
formula: LDL = total cholesterol −HDL cholesterol −
TG/2.2 [17].
Hyperlipidaemia was defined as total cholesterol
≥5.0 mmol/L, LDL-cholesterol ≥3.5 mmol/L, or triglyc-
erides ≥1.1 mmol/L for subjects younger than 10 years
of age or ≥1.7 mmol/L for those older than 10 years of
age. Serum HDL-cholesterol levels were considered to
be low if they were <1.03 mmol/L in children older
than 10 years if the values were <1.03 mmol/L in males
or <1.29 mmol/L in females [17].
Statistical analyses
The statistical analyses were performed using SPSSX
software (SPSSX Inc., Chicago, IL, USA). The charac-
teristics of the study population were described using
frequency distributions for categorical variables and mean
and standard deviation (SD) values, medians, and ranges
for continuous variables, depending on whether the
data were normally distributed. The differences between
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t test or the Mann–Whitney U test, depending on the
distribution of the analysed variables. The chi-squared test
and Fisher’s exact test were used to examine the associa-
tions between the dichotomous variables. The inter-group
comparisons for parameters were conducted using ana-
lysis of variance (ANOVA) or repeated-measures analysis
of covariance (ANCOVA), as appropriate. Bonferroni’s
post hoc correction for multiple comparisons was also
applied when a significant F was found. A p < 0.05 was
considered to be statistically significant.
Results
One year interventional study: enrolment time or T0
The primary clinical and biochemical features of the
study groups are shown in Table 1. At baseline we
have not found differences in levels of physical activity,
food and dietary habits of the different Arms (data not
shown).
Mean BMI-SDS was 2.29 ± 0.58 (2.18 ± 0.53 in pre-
pubertal subjects and 2.31 ± 0.63 in pubertal subjects),
without differences between males (2.31 ± 0.70) and fe-
males (2.19 ± 0.46). Seventeen patients (12.8%, n = 9 males
and 8 females; median age, 12.5 years; age range, 8.8–
13.2 years) had acanthosis nigricans. However, eighteen
(13.5%) patients showed glucose metabolism abnormal-
ities: 15 (11.3%) patients showed IGT, and 3 (2.2%)
exhibited T2DM. BMIs were not significantly differentTable 2 Comparison of clinical and biochemical variables at b
(per protocol analysis)
Arm A Arm
T0 T1 T0
BMI (SDS) 2.32 ± 0.53 1.80 ± 0.36*** 2.23 ±
Acanthosis nigricans, n (%) 7 (13.2) 3 (5.6)** 6 (13.
IGT 6 (11.3) 4 (7.5) 5 (11.
T2DM 2 (3.8) 1 (1.9) 1 (2.2
Fasting glucose, mg/dL 90.62 ± 4.32 84.02 ± 4.23*** 89.63
Fasting insulin, μU/mL 27.60 ± 7.83 18.04 ± 3.44*** 26.71
HbA1c, %, mmol/mol 5.63 ± 0.54 5.37 ± 0.35** 5.70 ±
HOMA-IR, mean (range) 5.69 (3.60–9.92) 3.38 (2.64–5.38)*** 5.68 (
ISOGTT, SDS 1.40 ± 0.24 3.16 ± 0.83*** 1.42 ±
Insulinogenic index,
mean (range)
3.66 (1.90–9.25) 2.79 (1.84–8.27)* 2.54 (
Disposition index,
mean (range)
4.42 (2.25–11.97) 10.28 (5.36–21.65)*** 4.01 (
Total cholesterol (mmol/L) 4.39 ± 0.51 3.31 ± 0.59*** 4.36 ±
LDL cholesterol (mmol/L) 3.05 ± 0.60 2.87 ± 0.67 2.96 ±
Triglycerides (mmol/L) 1.54 ± 0.40 1.63 ± 0.45 1.48 ±
BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model of assessm
IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus. Cross-sectional stu
vs. Arm A. Arm B vs. Arm B, Arm C vs. Arm C: *p<0.05, **p<0.005, ***p < 0.0005; Arm
§§§p < 0.0005.between the patients with glucose metabolism abnor-
malities (2.31 ± 0.61) and without glucose metabolism
abnormalities (2.19 ± 0.57).
At T0, the median HOMA-IR values were 5.69 (range,
3.60–9.92), 5.68 (range, 2.00–10.90), and 5.78 (range,
4.21–8.89) for Arms A-C, respectively. Insulin sensitivity
was reduced (1.40 ± 0.24, 1.42 ± 0.22; and 1.56 ± 0.48 in
Arms A-C, respectively). The insulinogenic indices for
Arms A-C were 3.66 (1.90–9.25), 2.54 (1.91–10.2), and
3.12 (1.15–9.70), respectively, and the disposition indices
were 4.42 (2.25–11.97), 4.01 (0.83–11.72), and 3.79
(1.88–9.28). Regarding these indices we have not found
any significant differences between males and females,
whereas we discovered significant statistical differences
between prepubertal and pubertal subjects.
There were no significant differences among Arms A-C
in the total cholesterol level (4.47 ± 0.74 mmol/L; Arms
A-C: 4.39 ± 0.51, 4.36 ± 1.09, and 4.51 ± 0.79 mmol/L,
respectively), mean LDL cholesterol (3.05 ± 0.60, 2.96 ±
0.73, and 3.12 ± 0.81 mmol/L, respectively), or triglycer-
ides (1.54 ± 0.40, 1.48 ± 0.29, and 1.62 ± 0.51 mmol/L,
respectively).
One year interventional study: end time or T1
The comparison between clinical and biochemical fea-
tures of the study groups are shown in Tables 2 and 3.
The use of Policaptil Gel Retard® has proved extremely
safe. In fact, there was evidence of only sporadic andaseline and at the end of the study in the different arms
B Arm C
T1 T0 T1
0.57 1.99 ± 0.56*° 2.27 ± 0.74 2.18 ± 0.70°°°
3) 6 (13.3) 4 (11.4) 4 (11.4)
1) 4 (8.8) 4 (11.4) 3 (8.6)
) 1 (2.2) - -
± 3.17 86.72 ± 6.00§§§°°° 90.90 ± 5.71 90.12 ± 2.89°°°
± 9.36 22.09 ± 3.67**°°°§§§ 27.39 ± 8.61 25.91 ± 4.41°°°
0.52 5.40 ± 0.51* 5.68 ± 0.58 5.54 ± 0.50
2.00–10.90) 4.90 (3.15–6.26)*°°°§§§ 5.78 (4.21–8.89) 5.76 (4.00–6.19)°°°
0.22 1.74 ± 0.40***°°° 1.56 ± 0.48 1.43 ± 0.21°°°
1.91–10.2)## 2.40 (0.82–5.87) 3.12 (1.15–9.70) 2.95 (1.22–6.78)
0.83–11.72) 4.93 (1.53–7.27)*°°° 3.79 (1.88–9.28) 3.84 (1.69–5.82)°°°
1.09 3.58 ± 0.93** 4.51 ± 0.79 3.74 ± 0.86**°
0.73 2.92 ± 0.78 3.12 ± 0.81 2.99 ± 0.87
0.29 1.61 ± 0.43 1.62 ± 0.51 1.54 ± 0.58
ent for insulin-resistance; ISOGTT, Matsuda index; SDS, standard deviation score;
dy: Arm A vs. Arm B or Arm A vs. Arm C: ##p < 0.005. Longitudinal study: Arm A
A vs. Arm B or Arm A vs. Arm C: °p < 0.05, °°°p < 0.0005; Arm B vs. Arm C:
Table 3 Comparison of clinical and biochemical variables at baseline and at the end of the study in the different arms
(intention to treat analysis)
Arm A Arm B Arm C
T0 T1 T0 T1 T0 T1
BMI (SDS) 2.33 ± 0.57 1.89 ± 0.45*** 2.23 ± 0.57 1.99 ± 0.56*° 2.29 ± 0.77 2.21 ± 0.73°°°
Acanthosis nigricans, n (%) 8 (13.8)1 3 (5.1)*** 6 (13.3) 6 (13.3) 5 (13.1)2 4 (10.5)
IGT 7 (12.1)1 4 (6.9)* 5 (11.1) 4 (8.8) 4 (10.5) 3 (8.6)
T2DM 2 (3.4) 1 (1.7) 1 (2.2) 1 (2.2) 1 (2.6)2 1 (2.6)
Fasting glucose, mg/dL 91.23 ± 4.39 86.34 ± 4.69*** 89.63 ± 3.17 86.72 ± 6.00§§§ 90.12 ± 5.79 91.36 ± 2.98°°°
Fasting insulin, μU/mL 27.48 ± 7.92 20.23 ± 5.12*** 26.71 ± 9.36 22.09 ± 3.67**§§§ 27.46 ± 8.55 25.32 ± 4.19°°°
HbA1c, %, mmol/mol 5.66 ± 0.57 5.43 ± 0.39** 5.70 ± 0.52 5.40 ± 0.51* 5.69 ± 0.59 5.54 ± 0.50
HOMA-IR, mean (range) 5.76 (3.60–10.67) 3.73 (2.64–7.13)** 5.68 (2.00–10.90) 4.90 (3.15–6.26)*°°§§ 5.76 (3.21–8.89) 5.63 (3.11–6.37)°°
ISOGTT, SDS 1.42 ± 0.26 3.01 ± 0.85*** 1.42 ± 0.22 1.74 ± 0.40***°° 1.58 ± 0.49 1.43 ± 0.21*°°°
Insulinogenic index,
mean (range)
3.61 (1.70–9.25) 2.86 (1.84–6.78)* 2.54 (1.91–10.2)## 2.40 (0.82–5.87) 3.07 (1.13–9.70) 2.82 (1.13–7.05)
Disposition index,
mean (range)
4.48 (2.22–12.02) 9.13 (5.01–21.65)*** 4.01 (0.83–11.72) 4.93 (1.53–7.27)*°°° 3.80 (1.88–14.78) 4.14 (1.42–5.98)°°°
Total cholesterol (mmol/L) 4.38 ± 0.52 3.63 ± 0.68*** 4.36 ± 1.09 3.58 ± 0.93** 4.49 ± 0.80 3.67 ± 0.62**
LDL cholesterol (mmol/L) 3.17 ± 0.64 2.97 ± 0.71 2.96 ± 0.73 2.92 ± 0.78 3.17 ± 0.83 3.03 ± 0.94
Triglycerides (mmol/L) 1.58 ± 0.43 1.88 ± 0.49 1.48 ± 0.29 1.61 ± 0.43°° 1.68 ± 0.53 1.51 ± 0.67°°
BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model of assessment for insulin-resistance; ISOGTT, Matsuda index; SDS, standard deviation
score; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus. 1patient with acanthosis nigricans and IGT dropped out in the per protocol analysis for
non-compliance: 2patient with acanthosis nigricans and T2DM dropped out in the per protocol analysis for non-compliance. Cross-sectional study: Arm A vs. Arm B
or Arm A vs.Arm C: ##p < 0.005. Longitudinal study: Arm A vs. Arm A. Arm B vs. Arm B, Arm C vs. Arm C: *p < 0.05, **p < 0.005, ***p < 0.0005; Arm A vs. Arm B or
Arm A vs. Arm C: °p < 0.05, °°p < 0.005, °°°p < 0.0005; Arm B vs. Arm C: §§p < 0.005, §§§ p < 0.0005.
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(1 patients, 0.75%), feeling of abdominal distension
(2 patients, 1.5%), flatulence (2 patients, 1.5%), and diar-
rhoea (1 patient, 0.75%). These effects were transient, and
no patient had to discontinue the study.
There were statistically significant differences in
weight reduction among the arms at T1 (Figure 2). The
mean BMI-SDS was 1.94 ± 0.50, significantly less than
T0 (2.29 ± 0.58; P < 0.0001). For Arms A-C, the BMI-SDSsFigure 2 Basal and longitudinal comparison of body mass index (BMI
represent mean values and 95% confidence intervals. *p < 0.05; ***p < 0.001were 1.80 ± 0.36 (T0: 2.32 ± 0.53; p < 0.0001), 1.99 ± 0.56
(T0: 2.23 ± 0.57; p < 0.05), and 2.18 ± 0.70 (T0: 2.27 ± 0.74;
insignificant), respectively. Arm A subjects have signifi-
cantly reduced BMI-SDSs compared to Arm B (p < 0.05)
and Arm C subjects (p < 0.0001).
We did not observe a significant reduction of patients
with acanthosis nigricans (9.8% vs. 12.8%; p =NS): however,
the number declined significantly from 7 to 3 (5.6% vs.
13.2%; p < 0.005) in Arm A and not change significantly in) SDS of all of the patients in Arm A, Arm B, and Arm C. The bars
.
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significant reduction in HbA1c with respect to the T0
(5.36 ± 0.44% vs. 5.64 ± 0.53%, p < 0.0001). This reduc-
tion was significant in Arm A (5.37 ± 0.35% vs. 5.63 ±
0.54%; p < 0.005) and B (5.40 ± 0.51% vs. 5.70 ± 0.52%;
p < 0.05), but not in Arm C (5.54 ± 0.50% vs. 5.68 ± 0.58%).
Overall, there was a reduction in patients showing
glucose metabolism abnormalities (9.8% vs. 13.5%: 8.3%
have IGT, whereas 1.5% have T2DM). IGT was diagnosed
in 7.5% (vs. 11.3%), 8.8% (vs. 11.1%), and 8.6% (vs. 11.4%)
of all patients in Arms A-C, respectively, whereas T2DM
was diagnosed in 1 patient in Arms A (1.9% vs. 3.8%) and
B (2.2% vs. 2.2%). BMI was not significantly different in
patients with glucose metabolism abnormalities (1.93 ±
0.49) and without glucose metabolism abnormalities
(1.95 ± 0.57), even if we showed a significant difference in
respect to T0 in patients with glucose metabolism abnor-
malities (2.31 ± 0.61; p < 0.05), but not in those without
glucose metabolism abnormalities (2.19 ± 0.57).
The median HOMA-IR was significantly less than T0
in Arms A (3.38; range, 2.64–5.38; p < 0.0001) and B
(4.90; range, 3.15–6.26; p < 0.05) but not C (5.76; range,
4.00–6.19). Insulin and glucose levels were significantly
reduced in Arm A (18.04 ± 3.44 μU/mL vs. 27.60 ± 7.83
μU/mL, p < 0.0001; 84.02 ± 4.23 mg/dL vs. 90.63 ±
4.32 mg/dL, p < 0.0001, respectively), whereas in Arm B,
we observed a reduction in insulin (22.09 ± 3.67 μU/mL
vs. 26.71 ± 9.36 μU/mL, p < 0.005) but not in glucose
levels (86.72 ± 6.00 mg/dL vs. 89.63 ± 3.17 mg/dL). In Arm
C, insulin and glucose levels were not different (25.91 ±
4.41 μU/mL and 90.12 ± 2.89 mg/dL, respectively) in re-
spect to T0 (Figure 3).Figure 3 Basal and longitudinal comparison among the three arms (A
regarding HOMA-IR, insulinogenic index, disposition index, and Mats
intervals. *Arm A: *p < 0.05; **p < 0.005; ***p < 0.001. °Arm B: °p < 0.05; °°p <The insulin sensitivity was significantly ameliorated
in Arm A (3.16 ± 0.83 vs. 1.40 ± 0.24, p < 0.0001) and B
(1.74 ± 0.40 vs. 1.42 ± 0.22, p < 0.0001), with a significant
difference between the two arms (p < 0.0001). The in-
sulin sensitivity in Arm C did not change significantly
(1.43 ± 0.21 vs. 1.56 ± 0.48) (Figure 3).
Arm A showed a significant reduction in insulinogenic
index (2.79 [1.84–8.27] vs. 3.66 [1.90–9.25], p < 0.05).
Arms B and C had reductions from 2.54 (1.91–10.2) to
2.40 (0.82–5.87) and from 3.12 (1.15–9.70) to 2.95 (1.22–
6.78), respectively, which were not significant (Figure 3).
The disposition index was significantly higher in
Arm A [10.28 (5.36–21.65) vs. 4.42 (2.25–11.97) at
T0; p < 0.0001] and Arm B [4.93 (1.53–7.27) vs. 4.01
(0.83–11.72) at T0; p < 0.05]; however, there was no
significant change in Arm C [3.84 (1.69–5.82) vs. 3.79
(1.88–9.28) at T0] (Figure 3).
The mean total cholesterol was 3.73 ± 0.89 mmol/L
(Arms A-C: 3.31 ± 0.59 mmol/L, 3.58 ± 0.93 mmol/L,
and 3.74 ± 0.86 mmol/L, respectively). The LDL cholesterol
was 2.87 ± 0.67 mmol/L in Arm A, 2.92 ± 0.78 mmol/L in
Arm B, and 2.99 ± 0.87 mmol/L in Arm C, respectively,
not significantly reduced in respect to T0. Finally, the tri-
glyceride levels were 1.63 ± 0.45 mmol/L in Arm A, 1.61 ±
0.43 mmol/L in Arm B, and 1.54 ± 0.58 mmol/L in Arm C,
respectively, not significantly reduced with respect to T0.
Discussion
Our study confirms that weight reduction is more efficient
in individuals subjected to a LGI carbohydrate diet com-
pared to an ERD. Interestingly, Policaptil Gel Retard®
significantly potentiated the effectiveness of the LGI dietrm A, broken line; Arm B, dotted line; Arm C, solid line)
uda index. The bars represent mean values and 95% confidence
0.005; °°°p < 0.0005. ^Arm C 3: ^p < 0.05; ^^p < 0.005; ^^^p < 0.0005.
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LGI diet, significantly reduced the frequency of acanthosis
nigricans and the HbA1c levels in these patients. Further-
more, our data suggest that Policaptil Gel Retard® may
reduce the number of glucose metabolism abnormalities,
such as IGT and T2DM in obese patients. Although the
differences are not significant, our results potentially high-
light a new interesting effect of this polysaccharidic mac-
romolecules complex.
In fact, this effect of Policaptil Gel Retard® may be
related to a reduction in the post-meal glycaemic and
insulinaemic peaks. The attenuated pancreatic insulin
response was likely due to slow glucose absorption, given
that glucose absorption directly regulates pancreatic insu-
lin release [41].
Both the quantity and the quality of a carbohydrate
affect the postprandial glycaemia and the interaction
between the two appears to be synergistic. Carbohydrates
affect energy intake and body weight by their GI, and dif-
ferent carbohydrate foods can increase glucose and insulin
levels to varying degrees, even when the amount con-
sumed is similar [41]. A high-carbohydrate diet based on
high GI foods is digested and absorbed rapidly, resulting
in high glycaemic load and increased demand for insulin
secretion [42]. In insulin-resistant people who consume
high GI foods, the postprandial hyperglycaemia and insuli-
naemia are magnified, likely contributing to β-cell exhaus-
tion and the development of T2DM [42].
The changes in glucose and insulin levels may have
subsequent effects on food intake or may promote
weight gain and obesity [40]. Typically, a low GI diet
produces greater satiety, directly provoking greater in-
creases in cholecystokinin and post-meal fullness/satiation
[42-45]. In contrast, the rapid absorption of glucose from
a high GI meal may increase voluntary food intake by
rapid increases in glycaemia and insulinaemia in the post-
prandial period, leading to a reactive hypoglycaemia
that stimulates appetite and increases the daily caloric
intake [42,46].
Our data seem to suggest that Policaptil Gel Retard®
may help reduce insulinemic peaks, enhancing β-cell
function more effectively than the LGI diet alone does,
and particularly the ERD, which seems to be unable to
restore the insulin secretory reserve in patients with IGT
or T2DM. However, taking into account that IGT is un-
stable, particularly in adolescents, long-term and more
large-scale trials are required before more definitive
statements can be made. Anyway, it is interesting to note
that our data at baseline on the total of our patients and
on 3 Arms after randomization are very similar to those
reported by Brufani et al. with a cross-sectional study of
510 overweight and obese subjects aged 3–18 yr [47].
In the last decade, T2DM has emerged as an increas-
ingly common paediatric disease in Europe [10] andstudies have demonstrated that IGT in obese youths is
associated with severe insulin resistance, β-cell dysfunc-
tion, and altered abdominal and muscle fat partitioning
[48,49]. Obesity, which has become a problem in paedi-
atrics, is among the major risk factors for the develop-
ment of T2DM in children with a strong family history
for the disease [48].
Although the transition from normoglycaemia to IGT
and subsequently to diabetes in adults is usually a grad-
ual phenomenon that occurs over 5–10 years, the early
appearance/onset of T2DM in young people raises the
likelihood of an accelerated process that shortens the
transition time between these steps [48]. Thus, T2DM
in young people has emerged as a paediatric entity of
great concern in its own right throughout the developed
world [48].
Weiss et al. [48] showed that IGT in obese children
was a pre-diabetic transitional state to T2DM and that
the primary predictor for deterioration to T2DM was
the BMI z-score [48].
The role of the LGI diet, particularly in association
with Policaptil Gel Retard®, may be important for redu-
cing or slowing the progression from IGT to T2DM in
obese children. Many studies have shown that very low
carbohydrate diets, although they are ad libitum, seem
to be more efficacious than energy-restricted, low fat di-
ets over the short term [50-52], even in adults with
T2DM [52]. This finding was confirmed in our study
with regard to weight reduction and the amelioration of
glycaemic and insulinemic metabolism as shown by the
disposition index. Whereas at baseline the alterations in
insulin sensitivity were not correctly compensated for by
increases in the insulin response to glucose loading, the
end-of-study disposition index was a significant pre-
dictor of amelioration for those who received the LGI
diet that included Policaptil Gel Retard®. This observa-
tion may be important because the diet may slow the
rate of deterioration of β-cell function in obese children,
a rate that has been demonstrated to be faster in children
than in adults [48].
Nevertheless, the relatively small sample size may be a
limit of our study. Furthermore, although the data allow
to hypothesize an effect of Policaptil Gel Retard® for
ameliorating the glucoinsulinaemic metabolism, we can-
not even exclude a concomitant effect of weight loss in
these patients. A placebo group with a LGI diet alone or
a group treated with only Policaptil Gel Retard® and nor-
mal diet would be useful to better distinguish the effects
of this product.
Conclusions
Policaptil Gel Retard® may be useful for reducing weight
gain in obese children, particularly in conjunction with a
LGI diet. It may also be useful for ameliorating the
Stagi et al. Italian Journal of Pediatrics  (2015) 41:10 Page 11 of 12glucoinsulinaemic metabolism, reducing the use of
future pharmacological interventions. Nevertheless, our
results should be confirmed with additional studies that
include larger sample sizes and longer longitudinal follow-
up times.
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